antipsychotics

RECENT POSTS

Prescription Nation: 4 Billion A Year, Antipsychotics Lead Psych Meds


To share these mind-boggling (and I use the term advisedly, because so many of these drugs act on the mind) statistics, I’m passing along a press release just in from the American Chemical Society in full:

People in the United States took more prescription drugs than ever last year, with the number of prescriptions increasing from 3.99 billion (with a cost of $308.6 billion) in 2010 to 4.02 billion (with a cost of $319.9 billion) in 2011. Those numbers and others appear in an annual profile of top prescription medicines published in the journal ACS Chemical Neuroscience.

Journal Editor-in-Chief Craig W. Lindsley analyzed data on 2011 drugs with a focus on medications for central nervous system (CNS) disorders. So-called antipsychotic medicines — including those used to treat schizophrenia, bipolar disorder, obsessive-compulsive disorder, Tourette syndrome and some forms of depression — ranked as the fifth most-prescribed class of drugs by sales. Antidepressants, for conditions that include depression and anxiety, ranked No. 7.

XanaxTM, CelexaTM and ZoloftTM were the most-prescribed psychiatric medicines, with other depression and anxiety medications rounding out the top 10. Two antipsychotics were among the 10 drugs that Americans spent the most on, with AbilifyTM in fourth place. Lindsley explains that while antidepressants continued to be the most-prescribed class of CNS drugs in 2011, prescriptions for ADHD medicines increased by 17 percent and multiple sclerosis medications by 22.5 percent in sales from 2010. While expiring patents on major antipsychotics in the next few years will put pressure on drug makers to innovate, the industry should be heartened by the growth of the number of prescriptions and spending.

The full paper is here, including this chart of the top 10 drugs:

Top 10 drugs

Top 10 drugs in 2011 (Source: IMS Health via ACS Chemical Neuroscience)

Must-Read: Globe Series On Children and SSI

No one’s evil. Everyone means well. But many low-income children end up on psychiatric drugs at least in part, it seems, because if they’re medicated, their families are likelier to be approved for hundreds of dollars a month in disability payments.

That’s my takeaway from the first installment of the superlative, nuanced and deeply reported series by Patricia Wen now running in the Globe.

But I’m no expert. I asked for a reaction from Robert Whitaker, award-winning journalist and author most recently of Anatomy of an Epidemic, a new book that investigates the skyrocketing number of adults and children disabled by mental illness.
His response:

“I think the families–and our society–really need to look at the toll that this can take on the child. The child declared eligible for SSI is now going to be medicated on a constant basis–after all, the child is now seen as seriously mentally ill– and often the drug treatment may include a powerful antipsychotic. Over the long term, such drug treatment can cause a host of physical, emotional and cognitive problems, and you are also setting the child on a ‘career path’ of lifelong mental patient. I don’t think the families are thinking about that when they turn to SSI for financial help; they don’t see what that this will do to their child down the road. And our society should also take a look at the extraordinary long-term financial cost of putting a child onto this path of life-long disability.”

Today’s installment of the series describes the heavy use of “speech delay” as a reason to put a child on disability payments, and the frequent failure to follow up on whether the disability remains.